Clinical Trials Logo

Gastric Cancer Stage II clinical trials

View clinical trials related to Gastric Cancer Stage II.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06342427 Recruiting - Gastric Cancer Clinical Trials

Stomach Cancer Exosome-based Detection

DESTINEX
Start date: March 15, 2023
Phase:
Study type: Observational

Gastric cancer continues to have a poor prognosis primarily due to the inability to detect it in its early stages. This study will develop and validate a blood assay to facilitate the non-invasive detection of gastric cancer.

NCT ID: NCT06042998 Recruiting - Clinical trials for Gastric Cancer Stage III

A Multicenter, RCT Study of the Clinical Efficacy of Robotic and Laparoscopic Gastrectomy in Neoadjuvant Gastric Cancer

CLASS14
Start date: July 7, 2023
Phase: N/A
Study type: Interventional

To evaluate the clinical efficacy of robot radical Gastrectomy and laparoscopic radical Gastrectomy, patients with gastric adenocarcinoma (cT2N+M0 or cT3-4a/N+M0, phase II and III) undergoing neoadjuvant treatment were selected as subjects.

NCT ID: NCT04119622 Recruiting - Clinical trials for Gastric Cancer Stage III

Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric Cancer

Start date: October 8, 2019
Phase: Phase 2
Study type: Interventional

Gastric cancer (GC) is one of the most common malignancies. According to the global cancer statistics 2018, there were 1,033,701 new cases of gastric cancer per year, ranked the fifth place in new tumors, and 782,685 deaths, ranked the second place in cancer deaths. At present, surgery is the only way to cure gastric cancer, but the 5-year survival rate is only 20%-30%. studies have confirmed that neoadjuvant therapy could improve the R0 resection rate and overall survival, which is considered a better treatment strategy. PD 1 monoclonal antibody is definitely effective in neoadjuvant therapy in other tumors such as NSCLC and bladder cancer, especially in PD-L1+ patients. However, there is no research of PD-1 monoclonal antibody in neoadjuvant therapy of gastric cancer. Thus we plan to conduct this prospective phase II clinical trial, evaluating the safety and efficacy of toripalimab, also known as JS001, in combination with XELOX for the neoadjuvant therapy of gastric cancer.

NCT ID: NCT02969148 Recruiting - Clinical trials for Gastric Cancer Stage III

Laparoscopic Bursectomy and D2 Lymphadenectomy vs.Laparoscopic D2 Lymphadenectomy in Advanced Gastric Cancer

LBDL
Start date: November 2016
Phase: N/A
Study type: Interventional

To investigate the clinical efficacy and safety of laparoscopic bursectomy and D2 lymphadenectomy (LBDL group) versus laparoscopic D2 lymphadenectomy (LDL group) in advanced gastric cancer by prospective randomized controlled clinical trial.